Your session is about to expire
← Back to Search
CNTX-6970 for Knee Osteoarthritis Pain
Study Summary
This trial is testing a new pain medication for people with osteoarthritis of the knee. The goal is to see if it is safe and effective.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowExclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2019 Phase 3 trial • 622 Patients • NCT03006276Trial Design
Find a Location
Logistics
Other reimbursement is provided
Other forms of reimbursement are provided for this trial.
Who is running the clinical trial?
Media Library
- Agrees to have any information obtained from the study used for research purposesI can communicate well and follow study procedures.willing to use a mobile phone during the study periodI can understand the nature of the study and the protocol requirements, and I am willing to comply with the study drug administration requirements and discontinue any prohibited concomitant medications.I have tried 2 or more treatments that didn't work for me.I have chronic pain in my lower body that is as bad or worse than my knee pain.I have been on a stable dose of medication like duloxetine for conditions other than pain for at least 12 weeks.I have had moderate to severe knee pain for at least 6 months.I have a history of nerve damage in my knee joint.I have had moderate to severe knee pain for at least 6 months.I have not had a corticosteroid injection in the last 30 days.I am between 45 and 80 years old.My knee pain or function hasn't improved with current treatments.I have not experienced severe side effects from treatments.I am between 40 and 90 years old.You cannot have taken any experimental medications within the last 30 days or have any scheduled to be taken during the study.My knee pain is not due to osteoarthritis.I have not had a corticosteroid injection in my knee within the last 90 days.
- Group 1: Placebo
- Group 2: 300mg BID
- Screening: It may take up to 18 Weeks to process to see if you qualify in this trial.
- Treatment: You will receive the treatment for 168 Months
- Follow Ups: You may be asked to continue sharing information regarding the trial for 0 Weeks after you stop receiving the treatment.
Frequently Asked Questions
Is this study enrolling elderly people aged 75 and above?
"Applicants aged 4 to 80 can qualify for this trial. There are 46 separate trials available specifically for minors, while 682 clinical studies exist that cater to individuals over 65 years of age."
To what extent is the current clinical trial populated?
"This medical study requires 150 individuals with the appropriate qualifications. Participants can join from multiple sites, for instance Medical University of South carolina in Charleston and UTsouthwestern Medical Center in Dallas."
How has CNTX-6970 been deployed to benefit patients?
"CNTX-6970 is a common prescription for treating pain and also has some efficacy in regards to primary dysmenorrhoea, rheumatoid arthritis, and ankylosing spondylitis."
Has CNTX-6970 obtained regulatory authorization from the FDA?
"As this is currently a Phase 2 trial, with ample safety data but no evidence of efficacy yet, our team at Power assigned CNTX-6970 a score of 2."
Has CNTX-6970 been tested in any previous research studies?
"First tested in 2003 by the City of Hope Medical Group Inc, CNTX-6970 has since gone through 18496 clinical trials. At present, 40 are actively enrolling patients with numerous operating out of Charleston, South carolina."
Are there any opportunities available for those wishing to participate in this experiment?
"Yes, records available on clinicaltrials.gov indicate that recruitment is still ongoing for this trial, which was initially posted on October 25th 2021 and last updated September 21st 2022. 150 participants need to be sourced from 19 different medical sites."
Am I eligible to join this medical research initiative?
"Prospective participants should suffer from arthrosis and range in age between 4-80 years old if they wish to be admitted into this medical study. A total of 150 individuals are being enrolled."
What is the aim of this medical research?
"The primary outcome evaluated over the 24-week span of this trial is Treatment emergent adverse events (TEAEs). Secondary objectives encompass Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC-C) which assesses daily functioning using an 11-point numerical rating scale, PROMIS Sleep Disturbance Scale - 6A that correlates strongly with longer forms to determine sleep disruption, as well as Patient Global Impression of Change (PGIC), a single-item measure used to estimate treatment associated change."
How many medical centers are executing this experiment?
"The current recruitment sites for this trial include Medical University of South carolina in Charleston, UTsouthwestern Medical Center in Dallas and the University of California San Diego in La Jolla. In addition to these 3 centres, 19 other clinical facilities are onboarding participants."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
What questions have other patients asked about this trial?
Why did patients apply to this trial?
How responsive is this trial?
Average response time
- < 2 Days
Most responsive sites:
- University of Washington: < 24 hours
- Icahn School of Medicine at Mount Sinai: < 48 hours
- Montefiore Medical Center: < 48 hours
Typically responds via
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger